AI Can Accurately Estimate Bone Mineral Density and Classify Osteoporosis
By Lori Solomon HealthDay Reporter
WEDNESDAY, July 16, 2025 -- An artificial intelligence (AI)-assisted diagnostic system can accurately estimate bone mineral density (BMD) and classify osteoporosis category, according to a study published online July 9 in the Journal of Orthopaedic Research.
Toru Moro, M.D., Ph.D., from the University of Tokyo, and colleagues developed an AI-assisted diagnostic system that estimated lumbar spine and femoral BMD from anteroposterior lumbar X-ray images (1,454 images from 1,454 participants).
The researchers found that for the BMD estimation performance, the mean absolute errors were 0.076 g/cm2 for the lumbar spine and 0.071 g/cm2 for the femur between dual-energy X-ray absorptiometry-derived and AI-estimated BMD values. For the lumbar spine and femur of patients with osteopenia, performance showed a sensitivity of 86.4 and 80.4 percent, respectively, and specificities of 84.1 and 76.3 percent, respectively.
"Bone mineral density measurement is essential for screening and diagnosing osteoporosis, but limited access to diagnostic equipment means that millions of people worldwide may remain undiagnosed," Moro said in a statement. "This AI system has the potential to transform routine clinical X-rays into a powerful tool for opportunistic screening, enabling earlier, broader, and more efficient detection of osteoporosis."
Several authors disclosed ties to the KYOCERA Corporation.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Canagliflozin Tied to Reduction in HbA1c in Children, Teens With T2DM
WEDNESDAY, Aug. 6, 2025 -- Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c (HbA1c) for children and adolescents with type 2 diabetes mellitus...
About One in Six Men With Grade Group 1 Prostate Cancer Has Intermediate-, High-Risk Disease
WEDNESDAY, Aug. 6, 2025 -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online...
Follow-Up on Blood-Based Colorectal Cancer Screening Results Is Low
TUESDAY, Aug. 5, 2025 -- Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.